NAVY - BUMED 6530.16
(BUMED-M3) PATHOGEN REDUCTION TECHNOLOGY FOR APHERESIS PLATELETS
active, Most Current
| Organization: | NAVY |
| Publication Date: | 3 July 2018 |
| Status: | active |
| Page Count: | 3 |
scope:
Scope and Applicability.
Applies to all Navy medical treatment facilities (MTF) collecting and transfusing apheresis platelets.
Purpose.
This instruction sets the policy that apheresis platelets collected by Navy Blood Program managed blood donor centers be processed using Food and Drug Administration (FDA) approved pathogen reduction systems as per reference (a). It also establishes the requirements to use pathogen reduced apheresis platelets in transfusion services FDA-licensed through the Navy Blood Program.
Document History
BUMED 6530.16
July 3, 2018
(BUMED-M3) PATHOGEN REDUCTION TECHNOLOGY FOR APHERESIS PLATELETS
Scope and Applicability.
Applies to all Navy medical treatment facilities (MTF) collecting and transfusing apheresis platelets.
Purpose.
This instruction sets the policy that apheresis platelets...